These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21941964)

  • 41. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
    Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
    Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Searching for an ideal cervical cancer screening model to reduce false-negative errors in a country with high prevalence of cervical cancer.
    Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
    J Obstet Gynaecol; 2020 Feb; 40(2):240-246. PubMed ID: 31340702
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
    Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
    Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
    Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
    Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
    Latsuzbaia A; Hebette G; Fischer M; Arbyn M; Weyers S; Vielh P; Schmitt F; Mossong J
    Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Should women with atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion, receive reflex human papillomavirus-DNA testing?
    Liman AK; Giampoli EJ; Bonfiglio TA
    Cancer; 2005 Dec; 105(6):457-60. PubMed ID: 16104044
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improved abnormal Pap smear triage using cervical cancer biomarkers.
    Killeen JL; Dye T; Grace C; Hiraoka M
    J Low Genit Tract Dis; 2014 Jan; 18(1):1-7. PubMed ID: 23760145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analyses of atypical squamous cells refined by the 2001 Bethesda System: the distribution and clinical significance of follow-up management.
    Lee SJ; Jung KL; Lee JW; Song SY; Kim BG; Lee JH; Park CS; Bae DS
    Int J Gynecol Cancer; 2006; 16(2):664-9. PubMed ID: 16681744
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human papillomavirus testing in primary cervical screening and abnormal Papanicolaou management.
    Cox JT
    Obstet Gynecol Surv; 2006 Jun; 61(6 Suppl 1):S15-25. PubMed ID: 16729900
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlation of histopathologic/cytologic follow-up findings with vaginal ASC-US and ASC-H Papanicolaou test and HPV test results.
    Bansal M; Li Z; Zhao C
    Am J Clin Pathol; 2012 Mar; 137(3):437-43. PubMed ID: 22338056
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Accuracy of liquid-based Pap tests: comparison of concurrent liquid-based tests and cervical biopsies on 782 women with previously abnormal Pap smears.
    Guo M; Hu L; Martin L; Liu S; Baliga M; Hughson MD
    Acta Cytol; 2005; 49(2):132-8. PubMed ID: 15839615
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].
    Qian DY; Cen JM; Wang D; Zeng RH; Lin AH; Shu YH; Hong DH; Huang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):34-7. PubMed ID: 16635326
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of Cervical Neoplasia by Human Papillomavirus Testing in an Atypical Squamous Cells-Undetermined Significance Population: Results of the Becton Dickinson Onclarity Trial.
    Wright TC; Stoler MH; Parvu V; Yanson K; Eckert K; Kodsi S; Cooper CK
    Am J Clin Pathol; 2019 Jan; 151(1):53-62. PubMed ID: 30189049
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.
    Cox JT;
    Arch Pathol Lab Med; 2003 Aug; 127(8):950-8. PubMed ID: 12952506
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical performance of hybrid capture 2 human papillomavirus testing for recurrent high-grade cervical/vaginal intraepithelial neoplasm in patients with an ASC-US Papanicolaou test result during long-term posttherapy follow-up monitoring.
    De Vivar AD; Dawlett M; Wang JP; Jack A; Gong Y; Staerkel G; Guo M
    Arch Pathol Lab Med; 2015 Feb; 139(2):219-24. PubMed ID: 25611104
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
    Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
    JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S43-9. PubMed ID: 23519304
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.
    Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LC; Cuzick J; Myers O; Castle PE; Wheeler CM;
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):36-42. PubMed ID: 26518316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.